Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.
Authors
Planchard, DBrown, K
Kim, D
Kim, S
Ohe, Y
Felip, E
Leese, P
Cantarini, M
Vishwanathan, K
Jänne, P
Ranson, Malcolm R
Dickinson, P
Affiliation
Department of Medical Oncology, Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, FranceIssue Date
2016-02-22
Metadata
Show full item recordCitation
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. 2016 Cancer Chemother PharmacolJournal
Cancer Chemotherapy and PharmacologyDOI
10.1007/s00280-016-2992-zAdditional Links
http://link.springer.com/10.1007/s00280-016-2992-zType
ArticleLanguage
enISSN
0344-57041432-0843
ae974a485f413a2113503eed53cd6c53
10.1007/s00280-016-2992-z